API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

1

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Spexis

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Spexis Reports Solid Safety and Pharmacokinetics Results from First-In-Human Study with Inhaled Murepavadin, a Novel Macrocycle Compound

Details:

Inhaled Murepavadin is an antibiotic targeting pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis. It binds to LptD and inhibits lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the bacterium and ultimately, cell death.

Lead Product(s): Murepavadin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2023

ASK
US

Upload
your Marketing & Sales content

Polyphor

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

Details:

The phase I study will evaluate the safety and tolerability of single and multiple ascending doses of inhaled murepavadin in healthy volunteers and will be jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).

Lead Product(s): Murepavadin

Therapeutic Area: Infections and Infectious Diseases Product Name: POL7080

Highest Development Status: Phase IProduct Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 22, 2020

ASK
US

Upload
your Marketing & Sales content

Polyphor

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic murepavadin to Treat Pseudomonas

Details:

Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis.

Lead Product(s): Murepavadin

Therapeutic Area: Infections and Infectious Diseases Product Name: POL7080

Highest Development Status: PreclinicalProduct Type: Peptide

Partner/Sponsor/Collaborator: CF Foundation

Deal Size: $3.3 million Upfront Cash: Undisclosed

Deal Type: Funding November 24, 2020

ASK
US

Upload
your Marketing & Sales content